Tags: Drug.

cBR96-doxorubicin immunoconjugate (BMS-182248/SGN-15) was an antibody-drug conjugate (ADC) directed to the Lewis-Y antigen designed for the treatment of cancer. The payload was doxorubicin which was connected with a hydrazone linker to cysteine residues of the Lewis-Y specific monoclonal antibody BR96. Clinical development of cBR96-doxorubicin immunoconjugate was discontinued.

ATC prefix
none

Loading...

This page contains content from the copyrighted Wikipedia article "CBR96-doxorubicin immunoconjugate"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.